Polatuzumab vedotin (Polivy)

At a glance

Polatuzumab vedotin (Polivy) is an antibody–drug conjugate, often shortened to ADC. It combines an antibody that recognises a target on cells with a cell-killing medicine. It is given by a trained team through a drip into a vein. Although it is targeted treatment, it can affect healthy tissues and needs careful monitoring.

Polivy is usually given as part of a combination regimen. Preventive medicines for infection, attention to nerve symptoms and prompt reporting of infusion-site pain are important. Your calendar needs to include the whole combination and the tablets or injections used between visits.

Follow your own treatment calendar and the advice from your care team. Keep your medicine names and treatment dates handy to share with other clinicians.

How it works

Polatuzumab binds to CD79b, a protein on certain B cells. Its linked payload, monomethyl auristatin E or MMAE, interferes with the structures needed for cell division. Other medicines in the regimen act in different ways, so the combination cannot be treated as interchangeable with Polivy alone.

The antibody, its chemical link and the attached medicine form one product. They are not separate medicines that you can take in different amounts yourself. Targeting helps deliver treatment to particular cells, but it does not mean that only cancer cells are affected. Side effects can come from the attached medicine, the antibody, your existing illness or accompanying treatment.

An ADC is different from an immune checkpoint inhibitor, even when both are given in the same treatment plan. A reaction or noticeable side effect is not proof that an ADC is working. Equally, having few side effects does not mean that treatment has failed.

Is this treatment suitable for me?

Polatuzumab vedotin is used in combination treatment for selected diffuse large B-cell lymphomas and certain high-grade B-cell lymphomas. The combination depends on whether the lymphoma is newly diagnosed or has returned, its risk features and previous treatment. Your oncologist will advise whether it is suitable for you, taking account of your cancer type, relevant test results, previous treatment, overall health and the applicable prescribing information and regulatory guidance in your country.

The team reviews tissue findings, previous therapy, general fitness, blood counts and liver function. Existing neuropathy can affect treatment decisions. Treatment should be avoided in moderate or severe liver impairment and must not be given during an active severe infection. The plan must also account for the suitability and risks of accompanying rituximab, chemotherapy and steroids. Not every patient needs a separate new CD79b test as a stand-alone prerequisite.

The discussion should cover the aim of treatment, the alternatives, likely appointments and how benefit will be assessed. A target found in a sample is one part of this decision; it does not guarantee a response. Tell the team what matters to you, including independence, work, caring responsibilities and the practical support available at home.

Before treatment

Bring a complete list of prescribed and non-prescribed medicines, vitamins, herbal products and allergies. Mention previous difficult reactions to infusions, infections, diabetes, liver or kidney problems and any pregnancy or breastfeeding. Explain symptoms you already have so a later change is easier to recognise.

Blood counts, liver and kidney function and infection history are assessed. Describe numbness, weakness or balance problems. Screening required for accompanying medicines, including hepatitis B assessment with rituximab, should be completed. Cardiac assessment may be needed when the regimen contains doxorubicin. Pregnancy status is checked before treatment if pregnancy is possible.

A nurse or pharmacist should explain the supportive medicines and which ones start before the treatment day. Ask your team to help you plan when to take each medicine. Make sure you know how to reach your hospital's urgent oncology service outside clinic hours. You may find it helpful to save the instructions on your phone or keep a copy at home. A family member or friend can help you remember them.

Discuss fertility preservation before treatment if future parenthood matters to you. Tell the team about dental problems and planned procedures. A procedure may need to be timed around blood counts and infection risk. Do not postpone reporting an active dental infection while waiting for the next routine appointment.

How treatment is given

A standard Polivy dose is 1.8 mg/kg every 21 days for six cycles. It may be combined with rituximab, cyclophosphamide, doxorubicin and prednisone or prednisolone, abbreviated R-CHP, or with bendamustine and rituximab in an appropriate plan. Some schedules continue rituximab alone for two further cycles after the six Polivy combination cycles. R-CHP does not include vincristine; do not assume that all the medicines in a similarly named CHOP regimen should be added.

The first infusion takes 90 minutes, with observation during and for at least 90 minutes afterwards. If tolerated, subsequent infusions may take 30 minutes, with observation for at least 30 minutes afterwards. An antihistamine and fever-reducing medicine are given before Polivy. Other parts of the combination can make the visit substantially longer.

Preventive treatment against Pneumocystis pneumonia and herpesvirus is recommended throughout Polivy treatment. G-CSF, an injection that supports white-cell recovery, is recommended with R-CHP and considered with bendamustine–rituximab. Patients at increased risk of tumour lysis need additional prevention. Obtain the exact start and stop dates for these medicines.

Treatment is delivered through a cannula in a vein, a central line or an implanted port, depending on the plan and available access. Staff check the medicine, your identity, blood results and recent symptoms before starting. The appointment includes preparation and monitoring, so it will usually take longer than the infusion itself.

Tell the nurse immediately if you notice burning, pain, swelling, redness, leakage or tightness around the infusion site. These can mean medicine is leaking outside the vein. Do not wait for the drip to finish. At home, report a site that becomes more painful, blistered or discoloured, even if it looked normal when you left.

Also report flushing, itching, shivering, chest or back discomfort, wheezing, dizziness or swelling during treatment. Staff can stop or slow the infusion and assess you. Do not adjust the pump or line yourself. If a line remains in place, follow its cleaning and dressing instructions and report fever, tenderness or drainage around it.

If an appointment is missed, contact the treatment unit to arrange the next dose. Do not simply wait for the following cycle or seek an extra dose elsewhere. The correct restart date depends on why the dose was missed, the treatment schedule and recovery from side effects.

Monitoring your treatment

Blood tests usually check infection-fighting cells, red cells, platelets, kidney function and liver function. Some abnormalities cause no early symptoms. A reassuring blood test does not make a new symptom safe to ignore, and feeling well is not a reason to miss monitoring.

Blood counts and liver tests are reviewed, and the team asks about infections, tingling, weakness and daily function. The infusion site is watched closely because leaked medicine can injure tissue. Response assessments follow the complete regimen. Monitoring for companion-drug effects, such as heart function with doxorubicin, is additional to Polivy-specific checks.

Your team compares examinations, symptoms and relevant scans or disease tests over time. Ask when the first response assessment is planned and what the result could change. A treatment break or lower dose may protect you from accumulating harm while allowing further treatment. It is not automatically evidence that the cancer has worsened. Never try to compensate for a reduced dose with supplements or closer appointments.

Common side effects

Side effects vary between people and between treatment combinations. You may experience several, a few or none of those described. Tell the team about symptoms that interfere with eating, sleeping, walking or usual tasks; a problem does not need to be severe before support is worthwhile.

Nerve symptoms

Tingling, numbness, burning or weakness in the hands and feet can develop or worsen. Tell the team if you drop objects, struggle with buttons or feel unsteady. Neuropathy may require a pause, reduction or change in treatment and may take time to improve.

Infections and digestive effects

Low white cells can lead to infections. Take preventive medicines even when you feel well and report fever immediately. Nausea, diarrhoea or constipation can occur from the combination and supportive medicines. Ask your team how to manage these symptoms before changing any medicines.

Hair loss

Hair loss can occur with the complete regimen, particularly when it includes conventional chemotherapy. Ask about likely timing, scalp care and available support. Hair loss does not measure treatment benefit, and regrowth may take time after the course ends.

Tiredness and reduced stamina

Plan important tasks for the part of the day when you have most energy and accept practical help. Short periods of gentle activity can be useful, with rest between them. Sudden marked weakness, breathlessness, dizziness or a racing heart needs assessment for causes such as anaemia, infection or dehydration. Do not assume every new limitation is ordinary treatment fatigue.

Nausea, appetite and bowel changes

Take prescribed anti-sickness medicines on the agreed schedule. Small regular meals, cool foods and frequent sips can be easier to manage. Tell the team if you cannot keep medicines or fluids down, are passing little urine or are losing weight. A dietitian can help when eating becomes difficult.

Record loose stools and whether there is pain, blood or fever. Severe diarrhoea, repeated vomiting or a swollen painful abdomen needs prompt advice. Constipation can be worsened by anti-sickness drugs and pain relief; use the bowel plan your team recommends. Do not repeatedly add laxatives or anti-diarrhoeal medicines without checking when there is significant pain or other new illness.

Low blood counts

A low white cell count can make infection progress quickly. Follow the urgent-help instructions below. Low red cells can cause tiredness, pallor or breathlessness; sometimes transfusions are needed. Low platelets can cause easy bruising, nosebleeds, bleeding gums or tiny red-purple spots. Report new bleeding and avoid starting aspirin or anti-inflammatory painkillers without checking. Do not stop a prescribed blood thinner yourself; the team must balance bleeding and clotting risks.

Mouth comfort and skin care

Use a soft toothbrush and the mouth-care products advised by your team. Report ulcers, white patches or soreness that limits eating, because infection or dehydration may need treatment. Avoid very hot, acidic or spicy foods if they sting. Moisturise dry skin with a simple fragrance-free product and protect it from strong sunlight. Painful skin, blisters or rapidly worsening redness need medical assessment rather than a new cosmetic product.

Important side effects

Severe infection and rare brain infection

Serious infections, including pneumonia and opportunistic infections, can occur. A rare brain infection called progressive multifocal leukoencephalopathy, or PML, can cause new problems with speech, memory, vision, strength or coordination. Report these promptly. If PML is suspected, the team withholds Polivy and accompanying chemotherapy; if confirmed, they are permanently stopped. Sudden stroke-like symptoms require emergency assessment regardless of the suspected cause.

Tissue injury if medicine leaks outside the vein

Extravasation can cause significant tissue damage, sometimes becoming apparent after the infusion. Report burning, pain, swelling or redness immediately during administration. At home, increasing pain, blistering or discolouration at the site needs prompt contact with the unit. Do not massage the area or apply heat or cold without instructions.

Liver injury and tumour lysis

Liver-test abnormalities can sometimes indicate serious injury. Report jaundice, dark urine or right upper abdominal pain. Rapid cell breakdown can disturb blood salts and kidney function; preventive treatment is used when risk is increased. Reduced urine, severe cramps, confusion or palpitations needs urgent assessment.

Severe infection or an allergic reaction

A serious infection can occur even without a high temperature, especially if steroids or fever-reducing medicines are being taken. New confusion, marked drowsiness, rapid breathing or collapse requires emergency care. Sudden throat swelling, severe wheezing or faintness can indicate a severe allergic reaction. These symptoms should not be managed by waiting at home for the next scheduled review.

Other medicines and vaccinations

Strong CYP3A inhibitors or inducers can alter exposure to MMAE. Some antifungals, antibiotics, antivirals and seizure medicines therefore need checking. The other regimen components also have important interactions. Live or live-attenuated vaccines should not be given during treatment. Do not add vincristine or substitute another regimen medicine based on an old prescription or a similar abbreviation.

Ask the oncology pharmacist to check new prescriptions, over-the-counter remedies and herbal or traditional products. Products described as natural are not necessarily safe with cancer treatment. Do not use an unproven supplement in place of an essential supportive medicine. Keep the team informed about medicines prescribed by other specialists so that advice is coordinated.

Discuss influenza, COVID-19 and other vaccines with the team. Non-live vaccines may be suitable, although the response can be reduced during treatment. Live vaccines require specific specialist advice. Timing after treatment depends on immune recovery and the complete regimen; there is no single waiting interval that is correct for every ADC-treated patient.

Everyday life

Eating does not determine absorption of this intravenous medicine. Aim for enough food and fluids, adjusting for nausea and following any kidney, heart or diabetes restrictions. Avoid a restrictive anticancer diet that causes weight loss. Discuss alcohol with the team, particularly if liver tests are abnormal or other medicines cause sedation.

Work may remain possible with flexible hours and time for appointments. Increase activity gradually and avoid tasks that become unsafe because of fatigue, poor balance or impaired vision. Do not drive if dizzy, sleepy, visually affected or unable to use the pedals safely. Sedating premedicines can also affect driving, so arrange transport for early appointments until you know the plan.

Keep the steroid, infection-prevention and G-CSF schedules together with the infusion calendar. Steroids can affect sleep, mood and blood sugar; ask about timing and monitoring. Protect numb feet from heat or injury and use stable footwear. Let the team know if weakness makes stairs or driving unsafe.

Discuss travel before booking, especially long journeys or travel far from urgent care. Carry your treatment summary and enough supportive medicines. Use careful hand hygiene and food safety; avoid close contact with people who are clearly infectious. Complete social isolation is not automatically required. Ask about additional precautions when blood counts are very low.

Sex is often possible if comfortable, with the pregnancy precautions below and any advice about infection or bleeding. Ask the team whether barrier protection is needed after a dose to reduce exposure to drug residues in body fluids; the interval depends on the treatment. Caregivers cleaning urine, stool or vomit should follow the unit's handling advice, wear gloves when instructed and wash their hands afterwards. Keep medicines away from children and pets.

Fertility, pregnancy and breastfeeding

Use effective contraception during treatment. US instructions specify at least three months after the final dose for a treated person who could become pregnant and at least five months for a treated man with a partner who could become pregnant. EU instructions specify at least nine months for women and six months for men. Do not breastfeed during treatment; the post-treatment restriction is two months under US instructions and three months under EU instructions. Companion medicines may require longer periods, so obtain a single coordinated plan.

Pregnancy should be discussed before treatment and reported promptly if it occurs or is suspected. Loss of periods does not reliably mean pregnancy is impossible. Vomiting or severe diarrhoea can interfere with oral contraception; seek advice about additional protection if this happens. Accompanying medicines may require longer precautions than the ADC itself, so obtain one clear end date for the complete regimen.

Fertility may be affected by treatment and previous therapies, and recovery cannot be guaranteed. Discuss sperm, egg or embryo preservation before starting when feasible. The interval for avoiding pregnancy is a safety precaution and does not itself establish whether fertility has recovered.

After treatment

Continue prescribed infection prevention for the period specified by the team; companion medicines can require precautions beyond the last Polivy infusion. Persistent neuropathy, low counts or liver abnormalities need follow-up. Report delayed changes at an infusion site rather than assuming that a completed course makes them irrelevant.

Keep attending the recommended blood tests, scans and clinical reviews. Retain a treatment summary with the exact ADC name, dates, significant reactions and any ongoing medication. Tell new clinicians about past treatment when an unexplained symptom is assessed. Continue contraception, breastfeeding restrictions and prescribed supportive medicines for their own specified periods, counted from the relevant final dose.

Recovery can be gradual and may involve physical rehabilitation, dietary support or help with anxiety and sleep. A follow-up visit is also an opportunity to discuss returning to work, travel and persistent symptoms. New severe symptoms still need urgent assessment between appointments; finishing treatment does not remove the need for the urgent-care plan.

Common questions